Table 4.
Association between WBC/NLR and selected cancers before and after high-sensitive C-reactive protein (hs-CRP) adjustment in a subset of individuals with hs-CRP information (n=425,417; 96% of all study participants)
| Cancer Site | Before hs-CRP Adjustment | After hs-CRP Adjustment | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total WBC, Per Quartile Increase | NLR, Per Quartile Increase | Total WBC, Per Quartile Increase | NLR, Per Quartile Increase | |||||||||
| HR | (95%CI) | p-trend | HR | (95%CI) | p-trend | HR | (95%CI) | p-trend | HR | (95%CI) | p-trend | |
| All Cancers | 1.05 | (1.03-1.06) | <0.0001 | 1.03 | (1.02-1.04) | <0.0001 | 1.04 | (1.03-1.06) | <0.0001 | 1.03 | (1.01-1.04) | <0.0001 |
| Lung | 1.14 | (1.08-1.02) | <0.0001 | 1.04 | (1.00-1.09) | 0.06 | 1.13 | (1.07-1.19) | <0.0001 | 1.03 | (0.99-1.08) | 0.19 |
| Breast | 1.05 | (1.02-1.08) | 0.0004 | 1.02 | (0.99-1.05) | 0.17 | 1.06 | (1.03-1.09) | 0.0001 | 1.02 | (0.99-1.05) | 0.12 |
| Kidney | 1.09 | (1.01-1.18) | 0.03 | 1.16 | (1.07-1.25) | 0.0002 | 1.08 | (0.99-1.17) | 0.07 | 1.13 | (1.04-1.22) | 0.003 |
| CLL/SLL | 2.79 | (2.45-3.18) | <0.0001 | 0.38 | (0.33-0.42) | <0.0001 | 2.79 | (2.44-3.19) | <0.0001 | 0.38 | (0.34-0.43) | <0.0001 |
Abbreviations: CI, confidence interval; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; WBC, white blood cell; CLL/SLL, Chronic lymphocytic leukemia/small lymphocytic leukemia